{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-071024","form_type":"8-K","ticker":"BCYC","cik":"0001761612","company_name":"BICYCLE THERAPEUTICS PLC","filed_at":"2023-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.437912+00:00","generated_at":"2026-06-14T01:23:04.929296+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Bicycle Therapeutics shareholders pass all 10 proposals at 2023 AGM","bullets":["Approximately 91.77% of outstanding ordinary shares voted; proposals passed with overwhelming support.","All three director nominees (Bourque, Jordan, Winter) re-elected; Winter received 27.2M votes for.","Advisory say-on-pay passed with 26.1M votes for vs. 1.97M against (93% approval).","PwC ratified as US auditor (28.0M for) and reappointed as UK statutory auditor.","Directors' remuneration policy approved with 26.1M for vs. 1.97M against (93% approval)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-071024","json":"https://secwatch.observer/filing/0001104659-23-071024.json","markdown":"https://secwatch.observer/filing/0001104659-23-071024.md","text":"https://secwatch.observer/filing/0001104659-23-071024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923071024/0001104659-23-071024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923071024/tm2318664d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T01:23:04.929296+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"10bcd437f82a7efb019134fa4b3bbccd957a39c0","claim":"BICYCLE THERAPEUTICS PLC shareholders approved To re-elect as a director Janice Bourque. at the 2023-06-13 meeting.","evidence_excerpt":"Proposal 1 – To re-elect as a director Janice Bourque. For Against Vote Withheld/Abstain 27,895,136 154,479 7,306","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923071024/0001104659-23-071024-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"},{"claim_id":"1a6e36b21ae622ca39194d20ce3b8d7139aa929b","claim":"BICYCLE THERAPEUTICS PLC shareholders approved To re-elect as a director Veronica Jordan. at the 2023-06-13 meeting.","evidence_excerpt":"Proposal 2 – To re-elect as a director Veronica Jordan. For Against Vote Withheld/Abstain 27,943,943 105,672 7,306","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923071024/0001104659-23-071024-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"},{"claim_id":"27ee490e60b8b9b380bbd3e34a6175f0859d4ebf","claim":"BICYCLE THERAPEUTICS PLC shareholders approved To receive and adopt the Company's U.K. statutory annual accounts and reports for the year ended December 31, 2022. at the 2023-06-13 meeting.","evidence_excerpt":"Proposal 8 – To receive and adopt the Company’s U.K. statutory annual accounts and reports for the year ended December 31, 2022. For Against Vote Withheld/Abstain 28,047,438 1,339 8,144","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923071024/0001104659-23-071024-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"},{"claim_id":"430cfe1ad2a2d5cb790c119243c444d825ff6d29","claim":"BICYCLE THERAPEUTICS PLC shareholders approved To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's definitive proxy statement. at the 2023-06-13 meeting.","evidence_excerpt":"Proposal 4 – To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s definitive proxy statement. For Against Vote Withheld/Abstain 26,083,084 1,965,019 8,818","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923071024/0001104659-23-071024-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"},{"claim_id":"6f10eb960fc958d1ee484cbcedc1765ba137fb30","claim":"BICYCLE THERAPEUTICS PLC shareholders approved To authorize the Audit Committee to determine the Company's U.K. statutory auditors' remuneration for the year ending December 31, 2023. at the 2023-06-13 meeting.","evidence_excerpt":"Proposal 7 – To authorize the Audit Committee to determine the Company’s U.K. statutory auditors’ remuneration for the year ending December 31, 2023. For Against Vote Withheld/Abstain 28,047,978 1,381 7,562","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923071024/0001104659-23-071024-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"},{"claim_id":"7ef22589d2550fb3cbcba5cb446efb8114db67a1","claim":"BICYCLE THERAPEUTICS PLC shareholders approved To approve the directors' remuneration report for the year ended December 31, 2022 (excluding the directors' remuneration policy). at the 2023-06-13 meeting.","evidence_excerpt":"Proposal 9 – To approve the directors’ remuneration report for the year ended December 31, 2022 (excluding the directors' remuneration policy). For Against Vote Withheld/Abstain 26,084,674 1,964,069 8,178","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923071024/0001104659-23-071024-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"},{"claim_id":"826a6e5598cf6842d7cb5196885ac8d720862337","claim":"BICYCLE THERAPEUTICS PLC shareholders approved To re-elect as a director Sir Greg Winter. at the 2023-06-13 meeting.","evidence_excerpt":"Proposal 3 – To re-elect as a director Sir Greg Winter. For Against Vote Withheld/Abstain 27,238,892 632,657 185,372","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923071024/0001104659-23-071024-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"},{"claim_id":"a69b58e58a16c9b13696f2675851e29531a166f1","claim":"BICYCLE THERAPEUTICS PLC shareholders approved To approve the directors' remuneration policy, which will take effect immediately after the end of the AGM. at the 2023-06-13 meeting.","evidence_excerpt":"Proposal 10 -– To approve the directors’ remuneration policy, which will take effect immediately after the end of the AGM. For Against Vote Withheld/Abstain 26,075,659 1,971,866 9,396","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923071024/0001104659-23-071024-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"},{"claim_id":"d582420bbcba25b2de493bc28896376ed2387294","claim":"BICYCLE THERAPEUTICS PLC shareholders approved To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company's U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders. at the 2023-06-13 meeting.","evidence_excerpt":"Proposal 6 – To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company’s U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders. For Against Vote Withheld/Abstain 28,045,082 4,528 7,311","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923071024/0001104659-23-071024-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"},{"claim_id":"fdc15673e8adf67282d28d11dd84e6552b0f5a0a","claim":"BICYCLE THERAPEUTICS PLC shareholders approved To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company's U.S. independent registered public accounting firm for the year ending December 31, 2023. at the 2023-06-13 meeting.","evidence_excerpt":"Proposal 5 – To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company’s U.S. independent registered public accounting firm for the year ending December 31, 2023. For Against Vote Withheld/Abstain 28,045,153 4,500 7,268","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923071024/0001104659-23-071024-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}